Skip to main content
Clinical Trials/NCT04515589
NCT04515589
Completed
Not Applicable

Central Aspects of Pain in Rheumatoid Arthritis

University of Nottingham1 site in 1 country95 target enrollmentAugust 11, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
University of Nottingham
Enrollment
95
Locations
1
Primary Endpoint
Psychometric properties of CAP-RA
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study seeks to measure the psychometric properties of a newly developed Central Aspects of Pain in Rheumatoid Arthritis (CAP-RA) questionnaire, and investigate the ability of this questionnaire to measure central mechanisms of pain and also to predict worse pain and fatigue outcomes in people with Rheumatoid Arthritis (RA).

Detailed Description

Persistent pain and fatigue are prevalent and disabling symptoms in people with Rheumatoid Arthritis, even in the absence of active inflammation. The investigators believe that these symptoms may be a result of abnormal pain processing by the Central Nervous System (CNS), in a process called central sensitization. The investigators have developed a short, self-report questionnaire to measure central pain mechanisms in people with RA. It is called Central Aspects of Pain in Rheumatoid Arthritis (CAP-RA), and was adapted from a pre-existing questionnaire called CAP-Knee (which measures central sensitization in people with chronic knee pain). This study aims to measure the psychometric properties of CAP-RA, and the ability of the questionnaire to predict worse pain in the RA population. Secondary objectives of the study include predicting worse fatigue in people with RA, deriving CAP-RA scoring recommendations, investigating other factors associated with persistent RA pain, the association between central sensitization and pain, and investigating the course of pain and fatigue in RA. Participants will be recruited from a Rheumatology clinic. At baseline and 12 weeks these participants will undergo quantitative sensory testing (QST, pain tests), ultrasound for synovitis, clinical assessments, laboratory tests for systemic inflammation and, complete a questionnaire booklet, including the CAP-RA questionnaire. Some participants will complete the CAP-RA questionnaire 1 week after the baseline visit to assess the test-retest reliability of the questionnaire. In addition, participants will provide weekly pain and fatigue self-report via text message (SMS) for 12 weeks.

Registry
clinicaltrials.gov
Start Date
August 11, 2021
End Date
September 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult (age≥18y) of any sex and ethnicity.
  • Satisfy EULAR criteria for RA.
  • Active RA, as defined as DAS28 ≥3.2 at baseline visit

Exclusion Criteria

  • Unable to give informed consent.
  • Insufficient understanding of spoken or written English to comply with the requirements of the study protocol
  • Unable or unlikely to complete the proposed 12-week study follow up (eg. moving house, terminal diagnosis, current or planned pregnancy).
  • Active comorbidity (e.g. uncontrolled diabetes mellitus, cancer, infection) requiring changes in medical treatment at baseline
  • Major active psychiatric condition (e.g. major depression)
  • Inability to meet the requirements of clinical assessments

Outcomes

Primary Outcomes

Psychometric properties of CAP-RA

Time Frame: 1 week test-retest

A detailed assessment of the psychometric properties of CAP-RA. Higher scores indicate stronger central mechanisms of pain

Bodily pain

Time Frame: 12 weeks

Numerical Rating Scale (0-10) of bodily pain - increasing severity

Secondary Outcomes

  • Swollen joints(12 weeks)
  • Quantitative Sensory Testing(12 weeks)
  • Fatigue(12 weeks)
  • Physical activity(12 weeks)
  • Functional status(12 weeks)
  • Change and trajectory of bodily pain(12 weeks)
  • Change and trajectory of fatigue(12 weeks)
  • Neuropathic pain mechanisms(12 weeks)
  • Mental health(12 weeks)
  • Central sensitization(12 weeks)
  • Joint inflammation(12 weeks)
  • Inflammation-Erythrocyte sedimentation rate(12 weeks)
  • Inflammation-CRP(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials